About Enlaza Therapeutics
Enlaza Therapeutics is a private company based in LA Jolla, California, incorporated in 2020 in Delaware. It has reported $134,299,237 raised in seven offerings on Form D since March 2021. Its chief executive is Sergio Duron.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Aug 29, 2025 | Sep 11, 2025 | $15,000,000fully sold | 1 | $15.0M | EquityRule 506(b) | Form D ↗ |
| Apr 5, 2024 | Aug 9, 2024 | $84,000,000of $110.0M target | 16 | $5.2M | EquityRule 506(b) | Form D ↗ |
| Oct 4, 2022 | Oct 13, 2022 | $0of $311K target | 1 | $0 | EquityRule 506(b) | Form D ↗ |
| Sep 30, 2022 | Oct 13, 2022 | $0target not set | 1 | $0 | EquityRule 506(b) | Form D ↗ |
| Jul 30, 2021 | Aug 13, 2021 | $0target not set | 1 | $0 | EquityRule 506(b) | Form D ↗ |
| Jun 10, 2021 | Jun 28, 2021 | $0target not set | 1 | $0 | EquityRule 506(b) | Form D ↗ |
| Mar 12, 2021 | Mar 25, 2021amended Nov 22, 2022 | $35,299,237of $61.3M target | 10 | $3.5M | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Total, seven offerings | $134,299,237 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Enlaza Therapeutics's Form D filed Sep 11, 2025.
MM
Marcos Milla
Director
SS
Stephen Squinto
Director
TR
Tighe Reardon
Executive officer
Also an executive officer at AeroRx Therapeutics and an executive officer and director at AristaMD.
JL
SC
Shelley Chu
Director
SD
Sergio Duron
Chief Executive Officer and director
JT
James Topper
Director
SM
Sanford Madigan
Executive officer